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Abstract 
The goal of CERVIS is to make a substantial, positive impact in the cervical cancer diagnostic 
space through the development of a minimally invasive, cost effective solution that enables 
women in low-resource settings to test for cervical cancer on a frugal and effective platform. In 
the developed world, there are a variety of options that can aid in early detection, including pap 
smears. However, due to the high cost and laboratory requirements that accompany this 
procedure, women in low-resource settings rarely have access to this preventative care or 
regular screenings for cervical cancer. Using new research about the changes in the vaginal 
microbiome, we aim to create a frugal, visual diagnostic screening tool for early stage cervical 
cancer as an alternative to the existing expensive, invasive, and clinic-dependent methods. 
Outcomes will be measured by partnering with a Kenyan NGO to collect data from several 
clinics. 
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Introduction 
Cervical Cancer is a global health issue that accounts for 7.5% of all female cancers worldwide 
[1]. The World Health Organization estimates that 90% of cervical cancer-related deaths occur in 
low and middle income countries, most of which could be prevented by HPV screening and early 
diagnosis [2]. Although cervical cancer is the third leading cause of cancer death in women, 
there is currently no low-cost, non-invasive screening method available [3]. Early detection of 
cervical cancer is crucial to save lives. Early detection can limit the the need for invasive 
procedures, significantly increase the chance for successful treatment, and reduce mortality. 
Additionally, the link between Human Papillomavirus and cervical cancer has been thoroughly 
established. Around one-half of individuals diagnosed with HPV infections have high-risk 
infections. HPV 16 and HPV 18, two of the most common strains of high risk HPV cause 70% of 
cervical cancers [1]. 
The goal of the Cervical Cancer Early Response Visual Identification System (CERVIS) is to 
detect early stage cervical cancer using changes in the vaginal microbiome during tumorigenesis. 
Research on the vaginal microbiome is a relatively new field, and studies show that 
Fusobacterium ​spp. is undetectable in vaginal swabs from a healthy vagina but constitutes 
 
The Development of CERVIS: Cervical cancer Early Response Visual Identification System 
approximately 17% of bacteria in a vaginal sample from a cervical cancer patient. 
Fusobacterium ​spp. is an anaerobic, gram-negative bacteria ​usually absent in healthy tissue but 
upregulated in instances of disease ​[4]​. ​Fusobacterium nucleatum is associated with 
inflammatory diseases including ​appendicitis and ulcerative colitis, as well as multiple cancers, 
including ​colorectal, oropharyngeal, and cervical cancers [5]. 
Studies show no significant difference between the microbial populations between the vagina 
and the cervix [6]. For this reason, the use of vaginal sampling instead of cervical sampling was 
included in the device design to reduce the dependency on a trained clinician, which is unique 
from other cervical cancer detection methods. Women will be able to acquire their own sample 
in a non-clinical setting. The goal is to keep CERVIS low cost and minimally invasive to adapt 
to the needs of the target population in low resource areas.  
The current target population is Kenya, due to the high incidence and mortality rate of cervical 
cancer. Cervical cancer ranks as the first most common female cancer in Kenyan women ages 15 
to 44 years old with over 5,000 cases diagnosed annually. Kenya also has an extremely high 
incidence rate of HPV 16/18, as it is more than double that of the United States and other 
developed countries. Currently, 68% of Kenyan women diagnosed with cervical cancer will die 
from the disease, making cervical cancer the first leading cause of cancer death in women [7]. 
Many of these deaths could be prevented by HPV screening and early diagnosis of cervical 
cancer; however there is a lack of a low cost, non-invasive diagnostic for low resource settings 
[8].  
Limitations of current methods - 
Pap smears and colposcopies​ are the most common methods of cervical screening used in 
developed nations to accurately detect both precancerous and cancerous cellular processes within 
a swab sample of the cervix [9]. Analysis of pap smears requires a high degree of technical and 
clinical knowledge to identify and swab the cervix correctly and analyze sample results and 
diagnose accordingly. Additionally, expensive equipment to analyze the sample and the 
availability to a laboratory is required for proper and effective analysis. Additionally, these 
procedures have a high number of false positives. Finally, on a personal level, pap smears and 
colposcopy are invasive, painful, and costly [10].  
HPV vaccinations ​in combination with cancer screenings are the greatest preventative measure 
against cervical cancer [11]. FDA approved vaccinations like Gardasil and Cervarix have been 
found to be nearly 100% effective at preventing cervical infections of HPV 16/18, the two strains 
most commonly associated with the development of cervical cancer. The Center for Disease 
Control recommends that all women through the age of 26 and all men through the age of 21 be 
vaccinated beginning between the ages of 11-15. While the HPV vaccine provides protection 
from HPV infection, it does not offer any therapeutic treatment of the virus or cervical cancer 
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[12]. Additionally, social stigmas prevent many from getting vaccinated [13]. The vaccine, 
delivered in a three-part series, must be delivered by a health care professional within a clinical 
setting, making it difficult for those with limited access to clinics and hospitals to receive the full 
dose of the vaccine. Additionally, the vaccine is costly, further creating a barrier to accessing 
vaccines in the developing world [13].  
Visual Inspection with Acetic Acid (VIA)​ of the cervix with acetic acid is an effective and 
inexpensive screening method in poorly resourced areas [14]. Trained health workers and nurses 
work in mobile screening camps in low income areas to perform this diagnostic test. The test is 
invasive and can cause some discomfort similar to the pap smear method because of the insertion 
of a self-retaining vaginal speculum. After insertion, acetic acid is applied to the cervix and 
watched for a reaction between the suspected lesion and the acetic acid [15]. Similar to the 
limitations of  the previous devices, VIA also requires a high degree of technical knowledge to 
properly administer the screening, must be done in a clinical environment, and is highly invasive. 
When administering the test, if acetic acid is not applied properly bubbles may still form and 
result in false-positives.  
Roche CINtec PLUS Cytology​ is a qualitative immunohistochemistry (IHC) test using the p16 
biomarker, which is a cancer biomarker specifically linked to Cervical cancer. The test is 
conducted using microscopic assessment of ​p16​INK4a​ protein in formalin-fixed, 
paraffin-embedded (FFPE) cervical punch biopsy tissues. The test confirms cervical 
abnormalities based on hematoxylin and eosin (H&E) stained slides. This test is a more specific 
alternative to pap smear, but is invasive, expensive, requires a clinician, and results in high rates 
of false positives [16]. 
Table 1: A Comparison Between Current Screening Devices  
Device Benefits Limitations  





Performed in a clinical setting 
 
Clinical and technical 
knowledge required for 
analysis 




Primary screening technique 
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Low sensitivity if 
administered incorrectly 
Roche CINtec PLUS 
Cytology 
Specific for Ki-67 and p16 
markers of HPV infection 
Invasive, Multiple clinic 
visits 
 
Specific for ​>​CIN-2 
The limitations of these current screening methods highlight the need for a less invasive and 
frugal point-of-care diagnostic device. While this device could be used to screen for cervical 
cancer in a variety of settings around the world, a device, such as CERVIS, would be particularly 
useful for women in low resource settings with limited access to clinics, health professionals, and 
other higher-grade medical care.  
Methods 
Microbial Cultures and Conditions - 
F. Nucleatum​ ATCC 25586 was streaked for isolation using a disposable sterile loop on 
Anaerobe Systems  Brucella Blood Agar (BRU) and Fusobacterium Selective Agar (FSA). 1
These plates were incubated at 37 degrees celsius under anaerobic conditions for 48 hours. 
Anaerobic conditions were met using an anaerobic chamber, with an internal environment 
comprised of 90% N2, 5% CO2, and 5% H2. BRU media was chosen as a positive control, 
supporting the growth of ​Fusobacterium​ ​spp​. [17]. FSA is an enriched selective medium for the 
isolation and presumptive isolation of ​Fusobacterium ​species, chosen to inform the formulation 
of CERVIS media [18]. The selective character of the FSA media is due to the presence of three 
antibiotics: vancomycin, josamycin, and neomycin. The concentrations of each of these 
antibiotics inhibit the growth of most other facultative anaerobes [19].  
Optimization of Anaerobicity​ - 
Several cytology applicators- soft bristle brush, polyester swab, and Wallach Papette cervical cell 
collector brush- were chosen to measure the amount of oxygen introduced into a semi-solid 
media in a closed glass tube. Anaerobe Systems Anaerobic Transport Media AS-911 includes 
resazurin, and was used to visually indicate the presence of oxygen in each sample tube. Each 
cytology applicator was tested under two conditions. In condition A, the cytology applicator 
handle was cut to fit inside the tube and upon inoculation was left in the tube. The cap was 
resealed after 15 seconds.In condition B, cytology brushes were inserted into the media and 
immediately removed. The cap of the tube was sealed after 15 seconds.  Tubes under conditions 
1 ​Media produced by Anaerobe Systems is manufactured and packaged in a deoxygenated 
environment. 
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A and B remained sealed at room temperature for 72 hours. Color change, indicated by the redox 
reaction of resazurin, was measured after 24, 48, and 72 hours. 
CERVIS Media 
CERVIS Media was developed as a transparent semi-solid selective media that incorporates the 
selective components from Anaerobe Systems’ FSA media, removing blood to facilitate 
increased transparency. The CERVIS media was tested in parallel under anaerobic and aerobic 
environments. Under both conditions, bristle brush swabs were cut to fit inside the tube. ​F. 
nucleatum​ cultures were swabbed to obtain isolated colonies. Under anaerobic conditions, tubes 
were inoculated, sealed, and placed in the 37 degree incubator for 72 hours inside the anaerobic 
chamber. Under aerobic condition, ​F. nucleatum​ cultures grown on BRU plates were removed 
from the anaerobic chamber and exposed to oxygen prior to inoculation in the CERVIS media. 
Tubes were inoculated, sealed, and placed in the 37 degree incubator outside the anaerobic 
chamber for 72 hours and monitored for growth.  
Results  
Media Selectivity  
Fusobacterium​ growth was observed on BRU and FSA. Small, white isolated colonies were 
observed after 72 hours. Larger colonies of the same morphology were observed on the BRU 
plate than the FSA plate.  
      
Figure 1: ​F. nucleatum​ Growth on BRU (left) and FSA (right) 
Optimization of Anaerobicity  
Table 1 shows oxygen exposure after 72 hours. Oxygen exposure was similar for all swab types 
under condition A. Under condition A, the polyester swab and the bristle brush introduced less 
oxygen into the system compared to condition B. The cervical cell brush introduced less oxygen 
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into the system under condition B. The cervical cell brush did not fit in the tube without size 
modification, raising future concerns of contamination and ease of use. The bottom of every tube 
does not show presence of oxygen, indicating that an anaerobic bacteria could grow there.  
Table 2: Aerobicity Results  








CERVIS Media  
F.​ ​nucleatum​ growth was observed in CERVIS media under both anaerobic and aerobic 
conditions. After 24 hours, regions of concentrated turbidity were observed surrounding the 
bristle brush in the bottom of the tube signifying microbial growth. Although growth was visible 
after 24 hours, tubes were left in the incubator for 72 hours, checked periodically after 24, 48, 
and 72 hours respectively. After 48 and 72 hours, growth was more well defined. Similar 
patterns of growth were observed in both anaerobic and aerobic conditions.  
Table 3: ​F. Nucleatum ​Growth Observed in CERVIS Media  
24 hours 48 hours 72 hours 
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Discussion 
A. Prototype  
The results above informed the final design prototype. The prototype includes the glass 
anaerobic tube, CERVIS semi-solid selective media, and a sterile soft-bristle brush. This 
prototype is designed for ease of use and limits the need for expensive laboratory materials. 
Semisolid media was determined as the best choice for the device because it allowed for easy 
visualization in a tube while still preventing the diffusion of oxygen when the swab is inserted.  
B. Sources of Funding 
This project was primarily funded by the Santa Clara University School of Engineering, which 
was supplemented with additional funds through the Xilinx grant. These funds were used to fund 
the laboratory materials required to conduct research inside the anaerobic chamber. Materials 
required for the development of the media and the tube were donated by Anaerobe Systems at 
zero cost to the research team. Additional funding is currently being pursued through the 
formation of a corporate partnership with a local molecular diagnostic company. Grant funding 
through the Massachusetts Medical Society (MMS), the American Medical Women’s 
Association (AMWA), and the Adell & Hancock Fund Scholarships are also being investigated 
as additional sources of funding to travel to the country of interest to further explore the needs of 
the target population.  
C. Limitations  
One of the primary limitations that comes along with the development of this device is the 
difference that exists between in vitro and in vivo results. While we can test ​fusobacterium ​spp. 
growth from a culture, it must also be tested with ​fusobacterium ​spp. from an infected cervix to 
fully understand how the device can be used. The field of vaginal microbiome research is new 
and it has only recently gained more attention. There are limited studies about variability and 
changes in the microbiome. In order to develop a highly accurate and reliable device, it is 
essential to realize that this variability exists. Without some of this knowledge it is difficult to be 
able to predict the variability that the device might encounter. For the purpose of the preliminary 
experiments conducted, the swabbing procedure was held constant. It is unlikely that these same 
conditions will be met after the device is implemented. 
Additionally, the ​Fusobacterium ​spp. Requires an incubation temperature of 37 degrees celsius. 
Further tests will investigate the minimal temperature requirements and the associated optimal 
growth period to attempt to eliminate this criteria. To initially combat this limitation, alternative 
incubation methods will be explored to expedite the pilot test including the potential use of 
portable neonatal incubators and/or placing one incubator for multiple subjects located in a 
central community space [20].  
 
The Development of CERVIS: Cervical cancer Early Response Visual Identification System 
C. Next steps 
Observing ​Fusobacterium ​spp. growth in CERVIS medium proved difficult because these are 
non-motile organisms. To improve the visibility of these microbes in CERVIS, the formula 
should be altered to include an indicator system. During the next phase of the project, the 
primary focus will be on developing a secondary, differential test to confirm the presence of 
fusobacterium in the patient’s vaginal microbiome. ​Fusobacterium ​spp.​ ​produces hydrogen 
sulfide in the presence of cysteine [21]. Ammonium iron sulfate reacts with hydrogen sulfide 
creating a black color change. An iteration of CERVIS media will be developed to include 
cysteine and ammonium iron sulfate to trigger the more obvious black color change, making it 
easier to visually identify the presence of ​Fusobacterium ​spp.​ ​[22]​.  
Further steps with this project will also work to incorporate a test for high risk HPV. This would 
allow the device to not only have the capabilities of detecting early stage cervical cancer, but 
also the ability to pick up on high risk HPV infections that are strongly linked to the 
development of cervical cancer [23]. Studies show the potential of using other species found in 
the vaginal microbiota as an indicator of HPV infection. ​Sneathia​ spp. has been described as a 
possible microbiological marker of high risk HPV strains associated with the development of 
cervical cancer and warrants consideration as a secondary biomarker to increase test specificity 
in future device iterations [24]. 
Partnering with a local NGO in Kenya will help further advance this project to develop an 
optimal device deployment and pilot testing strategy. Human subjects research standards and 
protocols will be taken. To see the maximum impact, an educational component teaching women 
about their anatomy, the risks of cervical cancer, and the importance of screening will be 
developed with the help of local community members for ensured cultural relevance and 
incorporated into the device implementation strategy. This program will extend to both patients 
and providers to increase screening uptake by the women living in the community and minimize 
the risk of false positive results. This is an important step in navigating cultural barriers and 
ensuring that the device is implemented in the most effective and ethical way. 
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